Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Expected to Post Earnings of -$0.16 Per Share

Wall Street analysts predict that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will post ($0.16) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Infinity Pharmaceuticals’ earnings, with estimates ranging from ($0.18) to ($0.14). Infinity Pharmaceuticals posted earnings per share of ($0.12) during the same quarter last year, which indicates a negative year over year growth rate of 33.3%. The business is expected to report its next earnings results on Tuesday, August 6th.

On average, analysts expect that Infinity Pharmaceuticals will report full year earnings of ($0.73) per share for the current financial year, with EPS estimates ranging from ($0.76) to ($0.71). For the next financial year, analysts expect that the company will report earnings of ($0.74) per share, with EPS estimates ranging from ($0.87) to ($0.54). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.19). The firm had revenue of $2.14 million for the quarter, compared to analyst estimates of $10.07 million.

Several research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 price objective on the stock in a research note on Thursday, March 28th. ValuEngine upgraded shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, June 3rd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $2.50.

Infinity Pharmaceuticals stock traded down $0.02 during trading hours on Friday, hitting $1.57. The company had a trading volume of 101,762 shares, compared to its average volume of 79,874. The firm has a market cap of $90.51 million, a PE ratio of -7.85 and a beta of 1.95. Infinity Pharmaceuticals has a fifty-two week low of $1.00 and a fifty-two week high of $2.92.

A number of institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its position in Infinity Pharmaceuticals by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,101,085 shares of the biotechnology company’s stock worth $1,299,000 after acquiring an additional 35,211 shares in the last quarter. Renaissance Technologies LLC grew its position in Infinity Pharmaceuticals by 8.4% in the first quarter. Renaissance Technologies LLC now owns 891,200 shares of the biotechnology company’s stock worth $1,675,000 after acquiring an additional 69,300 shares in the last quarter. Acadian Asset Management LLC grew its position in Infinity Pharmaceuticals by 12.5% in the first quarter. Acadian Asset Management LLC now owns 542,519 shares of the biotechnology company’s stock worth $1,020,000 after acquiring an additional 60,383 shares in the last quarter. Fosun International Ltd grew its position in Infinity Pharmaceuticals by 10.6% in the first quarter. Fosun International Ltd now owns 418,296 shares of the biotechnology company’s stock worth $786,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in Infinity Pharmaceuticals by 48.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 191,927 shares of the biotechnology company’s stock worth $361,000 after acquiring an additional 62,800 shares in the last quarter. Hedge funds and other institutional investors own 54.33% of the company’s stock.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

See Also: Back-End Load

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.